MetLife Inc. (MET) saw its stock trade at EUR 84.12 on September 29, 2026, reflecting a negligible decline of 0.08% against the prior close. The company recently reported strong second-quarter performance with adjusted earnings per share rising 20% to USD 2.43 and total assets reaching USD 759.4 billion as of June 30, 2026.
Investors are closely watching a preliminary estimate for Q3 variable investment income, which the company expects to be at least USD 600 million on a pre-tax basis. This metric is critical for MetLife given its heavy reliance on investment portfolio performance to drive overall earnings, with commercial mortgage loans accounting for 17% of its investments as of mid-2026.
Analyst sentiment remains constructive despite the flat daily trading action. Fitch Ratings affirmed MetLife's credit ratings with a stable outlook citing strong diversification, while Wall Street Zen upgraded the stock from hold to buy, setting an average price target of USD 104.31 against a current market cap of USD 61.7 billion.
📉 MetLife stock traded at EUR 84.12, down 0.08% on Sept 29, 2026.
📈 Q2 adjusted EPS surged 20% to USD 2.43 with USD 1.6B earnings.
💰 Company holds USD 759.4B assets and generated USD 2.2B operating cash flow.
🔮 MetLife estimates at least USD 600M pre-tax variable investment income for Q3.
🚀 Wall Street Zen upgraded MetLife to buy with a USD 104.31 price target.
📉 MetLife stock traded at EUR 84.12 on September 29, 2026, down 0.08% versus the previous close.
📈 Q2 adjusted EPS surged 20% to USD 2.43, driven by a 15% increase in adjusted earnings to USD 1.6 billion.
💰 The company holds USD 759.4 billion in total assets and generated USD 2.2 billion in operating cash flow during Q2 2026.
🔮 MetLife estimates at least USD 600 million in pre-tax variable investment income for the quarter ending September 30, 2026.
🏦 Commercial mortgage loans represent 17% of MetLife's investment portfolio as of the first half of 2026.
⭐ Fitch Ratings affirmed MetLife's credit ratings with a stable outlook, highlighting strong diversification across its business lines.
🚀 Wall Street Zen upgraded MetLife from hold to buy, establishing an average analyst price target of USD 104.31.
📊 The stock trades within a 52-week range of USD 67.33 to USD 100.93 with a market capitalization of USD 61.7 billion.
Bullish Signals
Q2 adjusted EPS rose 20% to USD 2.43.
Operating cash flow reached USD 2.2 billion in Q2 2026.
Fitch affirmed credit ratings with a stable outlook.
Wall Street Zen upgraded stock to buy.
Risk Factors
Commercial mortgages are 17% of portfolio, raising sector risks per Fitch.
GAAP net income fell to $705M in Q2 from $1.14B in Q1.
Bullish Signals
MetLife reported a significant 20% increase in Q2 adjusted EPS, reaching USD 2.43, demonstrating strong operational profitability.
The company generated substantial operating cash flow of USD 2.2 billion in the second quarter of 2026.
Fitch Ratings affirmed MetLife's credit ratings with a stable outlook, validating its strong diversification strategy.
Wall Street Zen upgraded MetLife from hold to buy, reflecting positive analyst sentiment and a target price above current levels.
Risk Factors
Commercial mortgage loans constitute 17% of the investment portfolio, exposing the company to potential sector-specific risks identified by Fitch.
GAAP net income dropped to USD 705 million in Q2 compared to USD 1.14 billion in Q1, highlighting volatility driven by investment results.
AMMB Holdings Bhd and MetLife International Holdings LLC are reportedly weighing strategic options for their joint-venture insurance businesses, AmMetLife Insurance Bhd and AmMetLife Takaful Bhd. Sources indicate the parties are considering all possibilities, including a potential sale of the venture, amidst a flurry of mergers and acquisitions in Malaysia's insurance sector.
The review follows a failed 2023 attempt to sell the joint venture to Great Eastern Holdings for RM1.12 billion due to regulatory hurdles. Since that termination, AMMB and MetLife have shifted focus back to building the business, appointing new leadership and consolidating their conventional insurance operations onto a shared platform while maintaining separate takaful entities for regulatory compliance.
Financially, AmMetLife Insurance reported a 5.9% year-on-year profit increase to RM37.8 million in FY2026, though gross written premiums declined by 3.6%. Conversely, the takaful arm narrowed its loss to RM6.3 million driven by strong top-line growth of 51.8% in gross written premiums. AMMB's total insurance segment profit rose slightly to RM105 million, representing 5% of the group's total FY2026 profit.
The joint venture faces headwinds including rising medical inflation and intensifying competition. In the first quarter of FY2027, AMMB's insurance profit fell significantly to RM8.6 million from RM32.4 million a year earlier, primarily due to lower investment income and net earned premiums. Despite these challenges, the recent operational restructuring suggests shareholders still see value in the business.
📉 AmMetLife FY2026 profit rose 5.9% to RM37.8m despite premium drop.
⚠️ Q1FY2027 insurance profit fell sharply due to lower investment income.
📉 Takaful loss narrowed to RM6.3m as premiums surged 51.8%.
⚠️ Business faces medical inflation, cost pressures, and intensifying competition.
📰 AMMB and MetLife are weighing strategic options for their insurance joint venture, including a possible sale.
🔄 The review is prompted by recent M&A activity in Malaysia's insurance sector following a failed 2023 exit attempt to Great Eastern.
👔 AMMB appointed Wan Saifulrizal Wan Ismail as CEO of AmMetLife Insurance in March, succeeding Rangam Bir.
💻 The group consolidated conventional insurance and takaful operations onto one shared platform while closing the agency channel.
📈 AmMetLife Insurance profit after tax rose 5.9% to RM37.8 million in FY2026 despite a 3.6% drop in gross written premiums.
📉 AmMetLife Takaful narrowed its loss to RM6.3 million in FY2026 as gross written premiums surged 51.8% to RM288.9 million.
📊 AMMB's total insurance segment profit increased slightly to RM105 million, accounting for 5% of the group's total FY2026 profit.
⚠️ In 1QFY2027, AMMB's insurance profit fell sharply to RM8.6 million due to lower investment income and net earned premiums.
🏥 The business faces challenges including rising medical inflation, cost pressures, and intensifying competition in the market.
Bullish Signals
MetLife maintains ~50% stake in AmMetLife ventures.
Risk Factors
Joint venture sale options being weighed with AMMB.
Previous sale deal failed due to regulatory issues.
Gross written premiums declined 3.6% in FY2026.
Q1FY2027 profit fell significantly to RM8.6 million.
Decline driven by lower investment income and premiums.
Bullish Signals
MetLife is maintaining a roughly 50% stake in AmMetLife Insurance Bhd and AmMetLife Takaful Bhd alongside AMMB.
The joint venture narrowed its loss to RM6.3 million in FY2026, driven by strong top-line growth with gross written premiums rising 51.8% to RM288.9 million.
AmMetLife Insurance reported a profit after tax increase of 5.9% year-on-year to RM37.8 million in FY2026.
Risk Factors
AMMB and MetLife are reportedly weighing options including a possible sale of their insurance joint venture business.
A previous deal to sell the venture to Great Eastern for RM1.12 billion failed due to regulatory issues in Malaysia and Singapore.
AmMetLife Insurance gross written premiums declined 3.6% year-on-year to RM774.8 million in FY2026.
In 1QFY2027, AMMB's insurance profit after tax fell significantly to RM8.6 million from RM32.4 million a year earlier.
The decline in Q1FY2027 profit was mainly due to lower investment income and net earned insurance premiums.
MetLife Inc. stock traded at USD 97.25 on the NYSE on September 24, 2026, approaching its 52-week high of USD 100.93 with a market capitalization of USD 62.57 billion. The insurer provided preliminary estimates for Q3 variable investment income of at least USD 600 million pre-tax, which serves as an early operating signal ahead of its scheduled results release on November 4, 2026.
In the second quarter of 2026, MetLife reported diluted GAAP EPS of USD 1.09 and consolidated net income of USD 779 million. On an adjusted basis, earnings reached USD 2.43 per share, representing a 20 percent year-over-year increase. The company achieved an adjusted Return on Equity (ROE) of 17 percent, hitting the top end of its annual target range between 15 percent and 17 percent.
Analyst sentiment remains positive with Piper Sandler upgrading MetLife to Overweight and setting a price target of USD 110.00, which implies significant upside from current levels. Additionally, Group Benefits adjusted earnings surged 25 percent year over year to USD 503 million, driven by a mortality ratio of 79 percent that outperformed the company's internal target range.
The article highlights MetLife's strong financial performance across investment income and underwriting metrics, supported by institutional upgrades. While the Q3 estimate is preliminary and unaudited, it suggests robust contribution toward the full-year guidance of USD 1.6 billion in pre-tax variable investment income.
📈 MetLife stock nears $100.93 high with $62.57B market cap.
💰 Q3 variable income projected at least $600M pre-tax.
📊 Q2 adjusted EPS rose 20% to $2.43.
🎯 Adjusted ROE hit top of target range at 17%.
🚀 Piper Sandler upgrades MetLife to Overweight with $110 target.
📈 MetLife stock traded at USD 97.25 on September 24, 2026, trading near its 52-week high of USD 100.93 with a market cap of USD 62.57 billion.
💰 The insurer estimated Q3 variable investment income at least USD 600 million pre-tax, contributing to full-year guidance of USD 1.6 billion.
📊 Q2 adjusted EPS rose 20 percent year over year to USD 2.43, with diluted GAAP EPS reaching USD 1.09.
🎯 Adjusted ROE hit 17 percent, achieving the top of the company's annual target range of 15 percent to 17 percent.
🚀 Piper Sandler upgraded MetLife to Overweight with a price target of USD 110.00, indicating analyst confidence in valuation upside.
🏆 Group Benefits adjusted earnings increased 25 percent year over year to USD 503 million in Q2 2026.
✅ The Group Life mortality ratio improved to 79 percent, beating the company's target range of 83 percent to 88 percent.
Bullish Signals
Stock trades near 52-week high of USD 100.93.
Q2 EPS surged 20% YoY to USD 2.43.
Adjusted ROE hit 17%, meeting annual target.
Group Benefits earnings jumped 25% YoY.
Piper Sandler upgraded to Overweight with USD 110 target.
Bullish Signals
MetLife stock is trading near its 52-week high of USD 100.93 at USD 97.25, indicating strong market confidence and momentum.
Q2 adjusted earnings per share surged 20 percent year over year to USD 2.43, demonstrating robust profitability growth.
The company achieved an adjusted ROE of 17 percent, successfully hitting the top end of its annual target range.
Group Benefits adjusted earnings jumped 25 percent year over year to USD 503 million, showing strong segment performance.
The Group Life mortality ratio improved to 79 percent, significantly outperforming the company's internal target range.
Piper Sandler upgraded MetLife to Overweight with a price target of USD 110.00, suggesting substantial upside potential from current levels.
Preliminary Q3 variable investment income is estimated at least USD 600 million pre-tax, supporting strong full-year guidance.
MetLife Inc. (NYSE: MET) shares gained 0.99 percent to close at USD 21.35 on September 23, 2026, trading above the prior session's close of USD 21.14. The stock opened at USD 21.07 and finished USD 0.21 higher, with a daily trading volume of 81,830 shares that significantly exceeded the average volume of 44,648 shares.
Despite the broader S&P 500 declining 0.8 percent to 7,706.03 on the same date, MetLife's performance outperformed the index by 1.79 percentage points. The stock traded within a session range of USD 20.94 to USD 21.47, remaining below its 52-week high of USD 24.29 but above the 52-week low of USD 20.38.
Analyst sentiment improved for the insurer following an upgrade from Neutral to Overweight by Piper Sandler on September 22, 2026. Market attention is also focused on upcoming U.S. economic data scheduled for release on September 24, including second-quarter current account figures and August new-home sales, which could influence rate-sensitive financial stocks like MetLife.
MetLife's preferred security also saw gains of 0.99 percent on the NYSE during this session. The company's ISIN is US59156R1086, and its stock price action reflects a resilient performance against a backdrop of mixed macroeconomic indicators.
📈 MetLife stock gained 0.99% to close at USD 21.35.
📊 Trading volume hit 81,830 shares, nearly double the average.
🏆 Stock outperformed S&P 500 by 1.79 percentage points.
🔼 Piper Sandler upgraded MetLife from Neutral to Overweight.
📅 Upcoming economic data may impact rate-sensitive MetLife stocks.
📈 MetLife stock closed at USD 21.35 on September 23, 2026, gaining 0.99 percent to finish above its prior close.
📊 Trading volume reached 81,830 shares, nearly double the average daily volume of 44,648 shares.
🏆 The stock outperformed the S&P 500, which fell 0.8 percent, by a margin of 1.79 percentage points.
📉 MetLife's share price remains USD 2.94 below its 52-week high of USD 24.29 and USD 0.97 above the 52-week low.
🔼 Piper Sandler upgraded MetLife from Neutral to Overweight on September 22, 2026, boosting analyst sentiment.
📅 Upcoming U.S. economic data releases on September 24 could impact rate-sensitive financial stocks including MetLife.
Bullish Signals
Stock gained 0.99% to close at USD 21.35.
Trading volume of 81,830 shares exceeded average daily volume.
Piper Sandler upgraded MetLife from Neutral to Overweight.
Bullish Signals
MetLife stock gained 0.99 percent to close at USD 21.35, outperforming the broader S&P 500 which fell 0.8 percent on the same day.
Trading volume of 81,830 shares significantly exceeded the average daily volume of 44,648 shares, indicating strong investor interest ahead of the open.
Piper Sandler upgraded MetLife from Neutral to Overweight on September 22, 2026, signaling improved analyst confidence in the company's prospects.
MetLife Inc. (MET) closed its shares at USD 95.92 on the NYSE on September 22, 2026, marking a slight decline of 0.75 percent from the prior session. The stock price hovered near the USD 96 level as investors digested mixed signals from the company's second-quarter financial results and recent analyst sentiment.
Financially, MetLife reported adjusted earnings per share (EPS) of USD 2.43 for the second quarter of 2026, which exceeded the consensus FactSet estimate of USD 2.30. However, total revenue came in at USD 13.65 billion, falling significantly short of the FactSet forecast of USD 19.67 billion, creating a divergence between profitability and top-line growth expectations.
Analyst sentiment has shifted positively following an upgrade to a Buy rating by Kabutan on September 22, 2026. The broader analyst consensus currently projects an average price target of USD 105.75, representing a potential upside of approximately 10.25 percent from the closing price, with individual targets ranging between USD 84.00 and USD 119.00.
The market is currently weighing the strength of MetLife's adjusted earnings beat against its underwhelming revenue performance. While the stock remains close to the USD 96 mark, the upgraded rating suggests that analysts view the company's profitability metrics as a more reliable indicator of value than the reported revenue shortfall at this time.
📉 MetLife stock closed down 0.75% at USD 95.92 on Sept 22, 2026.
💰 Q2 adjusted EPS of USD 2.43 beat analyst estimates.
📉 Q2 revenue of USD 13.65 billion missed the USD 19.67 billion estimate.
🔼 Kabutan upgraded MetLife to Buy rating on Sept 22, 2026.
🎯 Average price target is USD 105.75, implying 10.25% upside.
📉 MetLife Inc. closed at USD 95.92 on September 22, 2026, down 0.75 percent from the previous trading session.
💰 The company reported second-quarter adjusted EPS of USD 2.43, beating the FactSet estimate of USD 2.30.
📉 Reported revenue for Q2 2026 was USD 13.65 billion, missing the FactSet estimate of USD 19.67 billion.
🔼 Kabutan upgraded MetLife to a Buy rating on September 22, 2026, supporting recent bullish analyst sentiment.
🎯 The average analyst price target stands at USD 105.75, implying roughly 10.25 percent upside from the current close.
📊 Trading volume reached 253 million dollars on September 22, 2026, as investors assessed the mixed earnings report.
Bullish Signals
Kabutan upgraded MetLife to Buy on Sept 22, 2026.
Risk Factors
Revenue missed estimates by $6B in Q2.
Stock fell 0.75% due to revenue miss.
Bullish Signals
MetLife received a Buy rating upgrade from Kabutan on September 22, 2026, signaling renewed analyst confidence in the company's strategic direction.
The company beat adjusted EPS expectations with second-quarter results of USD 2.43 versus the consensus estimate of USD 2.30.
Analysts maintain an average price target of USD 105.75, suggesting a potential upside of 10.25 percent from the current trading price.
The stock is supported by strong profitability metrics that outperformed forecasts despite a revenue shortfall.
Risk Factors
MetLife reported second-quarter revenue of USD 13.65 billion, which was significantly below the FactSet estimate of USD 19.67 billion.
The stock declined 0.75 percent to close at USD 95.92 on September 22, 2026, reflecting market caution regarding the revenue miss.
MetLife Inc. stock traded at USD 97.08 on September 18, 2026, positioning the life insurer near its 52-week high of USD 100.93 with a market capitalization of USD 62.47 billion. The company recently reported strong financial performance for the second quarter of 2026, beating analyst expectations and demonstrating robust operational metrics that support its current valuation.
For the second quarter of 2026, MetLife earned USD 2.43 per share, surpassing the consensus estimate of USD 2.30 by USD 0.13. Revenue increased 10.5 percent year over year to reach USD 13.52 billion, while net margins improved to 4.57 percent and return on equity climbed to 23.39 percent, highlighting a healthy operating profile.
Analyst sentiment remains largely positive despite the stock trading close to its yearly peak. The consensus rating is Moderate Buy with an average 12-month price target of USD 102.77. While Wall Street Zen recently cut its rating to Hold, major institutions like Morgan Stanley and Wells Fargo have raised their price targets to USD 111.00 and USD 109.00 respectively.
MetLife is scheduled to report earnings again on November 9, 2026. Until then, investors are focusing on the gap between the current stock price and the analyst consensus target, as well as the proximity to the 52-week high, which serves as a key reference point for near-term trading activity.
📈 MetLife traded at $97.08, just below its $100.93 52-week high.
💰 Q2 EPS beat estimates at $2.43 with revenue up 10.5%.
🏆 Net margin improved to 4.57% and ROE reached 23.39%.
🎯 Average analyst target is $102.77, indicating upside potential.
📅 Next earnings report scheduled for November 9, 2026.
📈 MetLife stock traded at USD 97.08 on September 18, 2026, placing it just below its 52-week high of USD 100.93.
💰 Q2 2026 EPS reached USD 2.43, beating the consensus estimate of USD 2.30 by USD 0.13.
📊 Revenue grew 10.5 percent year over year to USD 13.52 billion in the second quarter of 2026.
🏆 Net margin improved to 4.57 percent with return on equity reaching 23.39 percent for the quarter.
🎯 The average 12-month analyst price target is USD 102.77, suggesting upside potential from current levels.
📉 Wall Street Zen cut MetLife to Hold, though the broader consensus remains Moderate Buy with 11 buy ratings.
🚀 Morgan Stanley raised its price target from USD 103.00 to USD 111.00 following recent performance.
🏦 Wells Fargo lifted its price target from USD 101.00 to USD 109.00, reinforcing bullish sentiment.
📅 The next earnings report is scheduled for November 9, 2026, providing a key catalyst for traders.
📉 Daily volume was 7.31 million shares with the stock trading in a 50-day range of USD 92.24 to USD 100.06.
Bullish Signals
Q2 EPS beat estimates at USD 2.43.
Revenue rose 10.5% YoY to USD 13.52B.
Net margin expanded to 4.57% and ROE hit 23.39%.
Stock trades near 52-week high on strong fundamentals.
Risk Factors
Wall Street Zen downgraded MetLife to Hold.
Stock trades $3.85 below 52-week high.
Bullish Signals
MetLife reported Q2 2026 EPS of USD 2.43, beating the consensus estimate of USD 2.30 by USD 0.13.
Revenue rose 10.5 percent year over year to USD 13.52 billion in the second quarter of 2026.
Net margin expanded to 4.57 percent while return on equity reached 23.39 percent for the quarter.
The stock is trading near its 52-week high, indicating strong investor confidence in the company's fundamentals.
Morgan Stanley raised its price target from USD 103.00 to USD 111.00, signaling increased bullishness.
Wells Fargo lifted its price target from USD 101.00 to USD 109.00, supporting the Moderate Buy consensus.
The average 12-month analyst price target of USD 102.77 suggests potential upside from the current trading price.
Risk Factors
Wall Street Zen cut MetLife's rating to Hold, introducing a dissenting voice in the analyst consensus.
The stock is trading approximately USD 3.85 below its 52-week high, limiting immediate momentum near resistance levels.
MetLife Inc. (NYSE: MET) shares opened flat, gaining 0.1% to close at USD 97.35 on September 17, 2026, trading within its upper half of the 52-week range between USD 67.33 and USD 100.93. The stock outperformed broader benchmarks significantly over the year-to-date period, delivering a 25.93% gain compared to the S&P 500's 11.57%, while also posting a strong one-year return of 27.26% versus the index's 15.72%. Trading volume reached approximately 2.76 million shares, reflecting steady investor interest in the life insurer.
Market sentiment remains anchored by the company's recent Q2 2026 financial performance, which saw earnings beat consensus expectations of USD 2.30 per share with actual results of USD 2.43 per share. Quarterly revenue was reported at around USD 19.07 billion, reinforcing positive investor confidence ahead of the next scheduled earnings release on November 9, 2026. The stock's valuation is further supported by a regular annual dividend of approximately USD 2.37 per share and a newly authorized USD 3.0 billion share buyback program for 2026.
Broader macroeconomic factors continue to influence MetLife's trading environment, with recent declines in bond yields and oil prices providing a supportive backdrop for financial stocks. While the S&P 500 advanced 1.14% and the Nasdaq Composite climbed 1.69% on September 17, MetLife lagged these broader equity benchmarks despite its modest uptick. Investors are currently positioning ahead of the upcoming November earnings update, monitoring how interest rate expectations and equity market risk appetite will impact the insurer's future performance.
📈 MetLife stock closed at USD 97.35, edging up 0.1% on September 17, 2026.
🚀 Company delivered 25.93% year-to-date gain versus S&P 500's 11.57%.
💰 Q2 2026 earnings of USD 2.43 per share beat consensus expectations.
💸 Board authorized USD 3.0 billion share buyback program for 2026.
🏦 MetLife pays regular annual dividend of around USD 2.37 per share.
📈 MetLife stock closed at USD 97.35 on September 17, 2026, edging up 0.1% with a day range between USD 96.80 and USD 98.32.
🚀 The company delivered a 25.93% year-to-date gain versus the S&P 500's 11.57%, highlighting strong relative outperformance over the current fiscal year.
💰 MetLife reported Q2 2026 earnings of USD 2.43 per share, beating consensus expectations of USD 2.30 per share.
📊 Quarterly revenue for the second quarter of 2026 was reported at approximately USD 19.07 billion.
💸 The company's board has authorized a USD 3.0 billion share buyback program for 2026 to support shareholder value.
🏦 MetLife pays a regular annual dividend of around USD 2.37 per share, providing consistent income to investors.
📅 The next scheduled earnings date is set for November 9, 2026, as per the Nasdaq-based earnings calendar.
📉 Despite its modest gain, MetLife lagged the S&P 500's 1.14% advance and the Nasdaq Composite's 1.69% climb on September 17.
🌍 Recent declines in bond yields and oil prices have created a supportive macroeconomic backdrop for financial stocks like MetLife.
Bullish Signals
EPS beat consensus at USD 2.43 vs USD 2.30.
Bullish Signals
MetLife reported Q2 2026 earnings of USD 2.43 per share, beating consensus expectations of USD 2.30 per share.
The company delivered a 25.93% year-to-date gain versus the S&P 500's 11.57%, demonstrating strong relative outperformance.
MetLife has authorized a USD 3.0 billion share buyback program for 2026 to support shareholder value.
The company reported quarterly revenue of around USD 19.07 billion in Q2 2026, confirming solid top-line growth.
MetLife offers a regular annual dividend of approximately USD 2.37 per share, providing consistent income to investors.
MetLife Inc. (MET) stock traded near its recent closing levels on September 11, 2026, as investors digested the company's latest quarterly financial results and dividend information. The insurer reported a quarterly earnings per share of USD 2.43, which beat the consensus estimate of USD 2.30 by USD 0.13. This performance highlighted a period of double-digit revenue growth and improved profitability for the global insurance and financial services group.
Financial metrics provided by MarketBeat indicate that MetLife's quarterly revenue reached USD 13.52 billion, representing a 10.5 percent increase from the same quarter a year prior. The company also reported a return on equity of 23.39 percent and a net margin of 4.57 percent for the latest quarter, demonstrating strong capital efficiency despite modest margins typical for large insurers.
MetLife continues to support its investment case with a quarterly dividend of USD 0.5925 per share, yielding approximately 2.4 percent annually based on current expectations. Analysts expect full-year earnings per share of USD 9.78, suggesting the company can maintain conservative payout ratios while distributing income. The stock closed within its established 52-week range, tracking broadly with the S&P 500 index as it consolidates following the earnings release.
Overall, the combination of rising earnings per share, solid return on equity, and a covered dividend forms the central narrative for MetLife's current valuation. Investors are weighing these positive fundamentals against the stock's consolidation phase while awaiting future catalysts such as updated guidance or capital management actions.
📈 EPS beat consensus by $0.13 at $2.43.
💰 Revenue rose 10.5% to $13.52 billion.
📊 ROE reached 23.39% with a 4.57% net margin.
💵 Quarterly dividend of $0.5925 offers 2.4% yield.
🔭 Full-year EPS guidance set at $9.78.
📈 MetLife reported quarterly earnings per share of USD 2.43, beating the consensus estimate of USD 2.30 by USD 0.13.
💰 Quarterly revenue reached USD 13.52 billion, marking a 10.5 percent increase from the same quarter a year earlier.
📊 The company achieved a return on equity of 23.39 percent and a net margin of 4.57 percent for the latest quarter.
💵 MetLife paid a quarterly dividend of USD 0.5925 per share, equivalent to an annualized yield of about 2.4 percent.
📉 The stock closed within its established 52-week range on September 11, 2026, tracking broadly with the S&P 500 index.
🔭 Analysts expect MetLife to deliver full-year earnings per share of USD 9.78 for the current fiscal year.
Bullish Signals
EPS beat estimates by $0.13 at $2.43.
ROE reached 23.39% with a 4.57% net margin.
Revenue rose 10.5% year-over-year to $13.52B.
Quarterly dividend yield stands at 2.4%.
Bullish Signals
MetLife reported quarterly earnings per share of USD 2.43, beating the consensus estimate of USD 2.30 by USD 0.13.
The company achieved a return on equity of 23.39 percent and a net margin of 4.57 percent for the latest quarter.
MetLife reported quarterly revenue of USD 13.52 billion, marking a 10.5 percent increase from the same quarter a year earlier.
The company pays a quarterly dividend of USD 0.5925 per share with an annualized yield of about 2.4 percent.
MetLife Inc. (MET) operates as one of the world's largest life insurance and employee benefits companies, with significant operations in the United States and a broad international presence across Asia, Latin America, Europe, the Middle East, and Africa. The company offers a diverse portfolio including life insurance, disability and accident coverage, dental and vision plans, annuities, retirement products, and corporate income solutions.
In the U.S., MetLife is organized around Group Benefits, which serves employers and employees with health and welfare benefits, and Retirement and Income Solutions, which provides retirement risk transfer, structured settlements, stable value, and other institutional retirement needs. These segments collectively form a substantial portion of the company's earnings base, linking it to demand for workplace benefits and corporate pension funding activities.
Internationally, MetLife maintains strong positions in markets such as Japan, Mexico, and Chile, providing exposure to various savings, protection, and demographic trends while navigating currency, regulatory, and macroeconomic complexities. The company also reports MetLife Holdings, which includes closed-block or run-off products that are no longer actively sold but continue to impact earnings and capital management.
Investors evaluate MetLife primarily through underwriting performance, investment income, interest rates, capital returns, and the resilience of demand for protection and retirement products. The business model relies on effectively pricing risk, managing a large investment portfolio, and maintaining financial strength throughout economic cycles.
🏢 MetLife operates globally with major U.S. life insurance and benefits divisions.
🇺🇸 Group Benefits serves employers while Retirement Solutions handles institutional needs.
🌍 Strong international positions in Asia, Latin America, Europe, Middle East, and Africa.
💼 Holdings include closed-block products impacting earnings and capital management.
🏢 MetLife is one of the world's largest life insurance and employee benefits companies with significant U.S. operations and a broad international footprint.
🇺🇸 In the U.S., Group Benefits serves employers and employees while Retirement and Income Solutions focuses on institutional retirement needs like stable value and structured settlements.
🌍 MetLife holds strong positions in Asia (especially Japan), Latin America (Mexico, Chile), Europe, the Middle East, and Africa, diversifying revenue streams across global markets.
💼 The company reports MetLife Holdings, which includes closed-block or run-off products that continue to impact earnings and capital management despite not being actively sold.
📈 Analyst sentiment remains strongly positive with 77% of analysts rating MetLife a Buy, indicating confidence in the company's long-term prospects.
📊 Technical indicators show the stock price is above both the 50-day and 200-day moving averages, suggesting a strong long-term upward trend.
Bullish Signals
77% of analysts rate MetLife as Buy.
Stock trades above 50-day and 200-day moving averages.
Analyst sentiment remains strongly positive with 77% of analysts rating MetLife a Buy, indicating broad institutional confidence in the company's strategic direction.
Technical indicators show the stock price is trading above both the 50-day and 200-day moving averages, confirming a strong long-term bullish trend.
Risk Factors
MACD momentum is weakening, suggesting potential short-term consolidation or pullback despite the strong long-term uptrend.
RSI is currently neutral, indicating that the stock may be approaching overbought conditions or lacks immediate explosive upward momentum.
MetLife Inc. reported strong second-quarter 2026 financial results, with earnings per share (EPS) of USD 2.43, beating the consensus estimate by USD 0.13. Revenue for the quarter reached USD 13.52 billion, representing a 10.5% year-over-year increase. The company also posted a net margin of 4.57% and a return on equity of 23.39%, demonstrating solid profitability metrics.
Following the earnings release, MetLife's board authorized a USD 3 billion share repurchase plan while maintaining its quarterly dividend at USD 0.5925 per share. This commitment to capital returns signals confidence in the company's cash flow generation and shareholder value creation strategy amidst a challenging market environment.
Analyst sentiment remains positive, with a consensus Buy rating and an average price target of USD 102.21, which is significantly above the current stock price. Major institutions like Morgan Stanley and Wells Fargo raised their price targets following the report, citing strong operational performance and growth prospects.
At the KBW Insurance Conference, MetLife highlighted that its New Frontier plan is ahead of schedule, projecting 2025 EPS growth of 10% and free cash flow of nearly USD 5 billion. Management also reaffirmed a full-year variable investment income target of USD 1.6 billion and expected cost synergies from the PineBridge acquisition.
MetLife stock traded at USD 78.45 on September 8, 2026, trading below its 52-week high but well above its low. The market capitalization stood at USD 61.41 billion, reflecting investor confidence in the company's strategic initiatives and financial resilience.
📈 MetLife Q2 EPS beat consensus by USD 0.13 to reach USD 2.43.
💰 Revenue grew 10.5% year over year to USD 13.52 billion.
🔄 Company authorized a new USD 3 billion share repurchase plan.
🚀 Morgan Stanley raised price target to USD 111.00 after earnings.
🎯 New Frontier plan projects 10% EPS growth for 2025.
📈 MetLife reported Q2 2026 EPS of USD 2.43, beating the consensus estimate by USD 0.13.
💰 Revenue grew 10.5% year over year to reach USD 13.52 billion in the second quarter.
📉 The company achieved a net margin of 4.57% and a return on equity of 23.39%.
🔄 MetLife authorized a new USD 3 billion share repurchase plan for its shareholders.
💵 The quarterly dividend remains at USD 0.5925 per share, implying an annualized payout of USD 2.37.
📊 Analysts maintain a Buy consensus with an average price target of USD 102.21.
🚀 Morgan Stanley raised its price target from USD 103.00 to USD 111.00 following the earnings.
🏦 Wells Fargo increased its target from USD 101.00 to USD 109.00 in the same update.
🎯 The New Frontier plan is ahead of schedule with projected 2025 EPS growth of 10%.
💸 Management expects nearly USD 5 billion in free cash flow for 2025.
🤝 MetLife anticipates about USD 50 million in annualized cost synergies from the PineBridge deal.
📈 The stock closed at USD 78.45, trading below the 52-week high of USD 100.93.
Bullish Signals
Q2 EPS beat estimates by USD 0.13 at USD 2.43 per share.
Bullish Signals
MetLife beat Q2 EPS estimates by USD 0.13, reporting USD 2.43 per share versus a consensus of USD 2.30.
Revenue surged 10.5% year over year to reach USD 13.52 billion in the second quarter.
The company achieved a robust return on equity of 23.39% and a net margin of 4.57%.
MetLife authorized a substantial USD 3 billion share repurchase plan to return capital to shareholders.
Analysts maintain a Buy consensus with an average price target of USD 102.21, indicating upside potential.
Morgan Stanley raised its price target from USD 103.00 to USD 111.00 following the strong results.
Wells Fargo increased its target from USD 101.00 to USD 109.00, reinforcing positive analyst sentiment.
The New Frontier plan is ahead of schedule with a projected 2025 EPS growth of 10%.
Management forecasts nearly USD 5 billion in free cash flow for the year 2025.
MetLife expects to generate about USD 50 million in annualized cost synergies from the PineBridge acquisition.
MetLife Inc. shares are trading near the upper end of their recent range following a strong performance in Q2 2026, where the company reported earnings per share of USD 2.43, beating analyst consensus estimates by 2.53%. The results were released on August 5, 2026, providing investors with a fresh view of the insurer's profitability and capital generation capabilities.
Beyond the earnings beat, MetLife announced a significant capital return strategy involving a USD 3 billion share buyback authorization approved by its Board of Directors. This program allows the company to repurchase up to 4.8 percent of its outstanding shares through open market purchases, signaling confidence in its financial position and commitment to shareholder value.
Financial metrics for Q2 2026 highlight robust growth, with quarterly revenue reaching USD 13.52 billion, representing a 10.5 percent year-over-year increase. Additionally, the company declared a quarterly dividend of USD 0.5925 per share, offering an annualized yield of approximately 2.4 percent based on recent trading levels.
Analyst sentiment remains positive with a consensus Buy rating and a target price of USD 102.21, suggesting potential medium-term upside from current levels. Institutional ownership stands at nearly 95 percent, while notable investors like NEOS Investment Management increased their stakes, reinforcing confidence in MetLife's earnings trajectory and capital return profile.
📈 MetLife Q2 EPS beat estimates by 2.53% at USD 2.43.
💰 Board authorized new USD 3.0 billion share buyback program.
📊 Quarterly revenue rose 10.5% year-over-year to USD 13.52 billion.
💵 Declared quarterly dividend of USD 0.5925 per share.
🎯 Analysts maintain Buy rating with USD 102.21 target price.
📈 MetLife reported Q2 2026 earnings per share of USD 2.43, beating the consensus estimate of USD 2.37 by 2.53 percent.
💰 The Board of Directors authorized a new share buyback program of USD 3.0 billion on August 5, 2026.
📊 Quarterly revenue for Q2 2026 reached USD 13.52 billion, marking a 10.5 percent year-over-year increase.
💵 MetLife declared a quarterly dividend of USD 0.5925 per share, corresponding to an annualized yield of 2.4 percent.
🎯 Analysts maintain a consensus Buy rating with a target price of USD 102.21, indicating modest upside potential.
🏦 Institutional investors and hedge funds collectively own 94.99 percent of MetLife's outstanding shares.
📈 NEOS Investment Management LLC increased its stake by 13.5 percent in Q2 2026, purchasing an additional 10,646 shares.
🏢 MetLife operates as a global provider of insurance, annuities, and employee benefit programs with a broad product set.
📉 The stock is trading at USD 97.51, near the upper end of its projected 2026 range between USD 90.59 and USD 114.12.
Bullish Signals
MetLife beat Q2 2026 earnings expectations with EPS of USD 2.43 versus a consensus of USD 2.37, demonstrating strong operational performance.
The company generated quarterly revenue of USD 13.52 billion in Q2 2026, achieving a robust 10.5 percent year-over-year growth rate.
MetLife's Board authorized a substantial USD 3.0 billion share buyback program, allowing the repurchase of up to 4.8 percent of outstanding shares.
The insurer declared a quarterly dividend of USD 0.5925 per share, providing an attractive annualized yield of 2.4 percent to income-focused investors.
Analyst consensus maintains a Buy rating with a target price of USD 102.21, suggesting incremental upside from the current trading level of USD 97.51.
Institutional ownership remains high at 94.99 percent, and major investor NEOS Investment Management increased its stake by 13.5 percent in Q2 2026.
MetLife (MET) stock has delivered an 80.7% total return over the past five years, yet valuation models present a mixed picture regarding future upside. While earnings multiples appear reasonable, broader checks suggest the stock is not a clear bargain based on current metrics.
Using an Excess Returns intrinsic value model, MetLife appears undervalued by approximately 44%. The analysis projects a stable book value of $53.18 per share and a cost of equity of $3.99, resulting in an excess return of $4.43 per share that supports a fair value estimate of $169.91.
Conversely, traditional valuation metrics indicate the stock is roughly fairly valued with only a modest premium. MetLife currently trades at a P/E ratio of 17.6x, which is higher than the broader insurance industry average of 11.2x and the peer group average of 14.6x, suggesting the market has already priced in some of its strengths.
📈 MetLife delivered an 80.7% total return over the past five years.
💰 Fair value model implies a 44% discount to current pricing at $169.91.
📊 Company projects stable book value of $53.18 with 15.83% average ROE.
⚖️ MetLife trades at 17.6x P/E, above industry and peer averages.
🔮 Future performance depends on maintaining ROE exceeding cost of capital.
📈 MetLife stock has generated an 80.7% total return for investors over the past five years.
💰 An Excess Returns model estimates a fair value of $169.91 per share, implying a 44% discount to current pricing.
📊 The company projects a stable book value of $53.18 per share with an average return on equity of 15.83%.
⚖️ MetLife trades at a P/E ratio of 17.6x, which is above the industry average of 11.2x and peer average of 14.6x.
📉 Broader valuation checks assign MetLife a low value score of 2 out of 6, indicating it may not be a clear bargain on traditional metrics.
🔮 The stock's future performance depends on maintaining returns on equity that exceed its cost of capital to justify the intrinsic value case.
Bullish Signals
MetLife appears undervalued by 44.0% according to an Excess Returns intrinsic value model based on projected cash generation.
The company is expected to generate a stable book value of $53.18 per share, supporting a high return on equity profile.
Risk Factors
MetLife trades at a P/E ratio of 17.6x, which is significantly above the broader insurance industry average of 11.2x and peer group average of 14.6x.
Broader valuation checks assign the stock a low value score of 2 out of 6, suggesting it may not be a clear bargain on traditional metrics.
MetLife (NYSE:MET) has surged 25.2% year to date, driven by a favorable shift in the interest rate environment where higher Treasury yields act as a direct tailwind for its investment income. The company reported that net investment income rose 10% to $5.36 billion in Q1 2026, while variable investment income surged 58% to $518 million. This performance highlights MetLife's ability to capitalize on elevated reinvestment yields behind its policy float, contrasting sharply with peers facing yield competition.
Management has demonstrated a strong commitment to shareholder returns, returning over $1.10 billion in the first quarter of 2026 alone. The company has also increased its dividend twice this year, raising the quarterly payout from $0.545 to $0.5925 per share. These actions reflect confidence in the sustainability of earnings as long as reinvestment yields remain elevated, positioning MetLife as a primary beneficiary of the current high-rate macroeconomic conditions.
The article positions MetLife as a clear winner among dividend payers reacting to the 30-year Treasury closing at 5.31% on August 17, 2026. While competitors like Realty Income and Verizon face pressure from competing yield alternatives or refinancing costs, MetLife's fixed-versus-floating mix and debt maturity schedule allow it to convert higher rates into immediate earnings growth. The stock's outperformance underscores the importance of specific balance sheet mechanics over broad sector labels in a high-yield environment.
📈 MetLife shares up 25.2% YTD as Treasury yields boost net investment income.
💰 Q1 2026 net investment income rose 10% to $5.36 billion.
📊 Adjusted EPS grew 23% year over year in Q1 2026.
💵 Management returned over $1.10 billion to shareholders in Q1 2026.
🔼 Quarterly dividend raised twice in 2026, increasing from $0.545 to $0.5925.
📈 MetLife shares are up 25.2% year to date as higher Treasury yields directly boost its net investment income.
💰 Q1 2026 net investment income rose 10% to $5.36 billion, with variable investment income surging 58% to $518 million.
📊 Adjusted EPS grew 23% year over year in the first quarter of 2026.
💵 Management returned over $1.10 billion to shareholders in Q1 2026 through dividends and buybacks.
🔼 The quarterly dividend was raised twice in 2026, increasing from $0.545 to $0.5925 per share.
🏦 MetLife benefits from a debt structure where higher reinvestment yields on its float increase earnings.
📉 Competitors like Realty Income face yield competition, whereas MetLife converts rates into profit.
Bullish Signals
Shares gained 25.2% YTD on higher Treasury yields.
Net investment income rose 10% to $5.36B in Q1.
Adjusted EPS grew 23% year over year in Q1.
Returned over $1.10B to shareholders in Q1.
Raised quarterly dividend twice in 2026.
Bullish Signals
MetLife shares have gained 25.2% year to date as the company benefits directly from elevated Treasury yields increasing its investment income.
Net investment income rose 10% to $5.36 billion in Q1 2026, driven by a 58% surge in variable investment income to $518 million.
Adjusted earnings per share grew 23% year over year in the first quarter of 2026.
The company returned over $1.10 billion to shareholders in Q1 2026, demonstrating strong capital allocation.
MetLife raised its quarterly dividend twice in 2026, increasing the payout from $0.545 to $0.5925 per share.
On August 17, 2026, MetLife, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission to announce dividend declarations for four of its preferred stock series. The filing details specific quarterly or semi-annual dividend rates and liquidation preferences for Series A, D, E, and F, providing precise financial terms for these capital instruments.
The company declared a quarterly dividend of $0.31471411 per share on its Floating Rate Non-Cumulative Preferred Stock, Series A, which carries a $25 liquidation preference. Additionally, a semi-annual dividend of $29.375 per share was announced for the 5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D, with a $1,000 liquidation preference.
MetLife also declared dividends for two high-value series: Series E received a quarterly dividend of $351.5625 per share on its 5.625% Non-Cumulative Preferred Stock with a $25,000 liquidation preference, while Series F was assigned a quarterly dividend of $296.875 per share on its 4.75% Non-Cumulative Preferred Stock, also with a $25,000 liquidation preference.
The Form 8-K was signed by Timothy J. Ring, Senior Vice President and Secretary of MetLife, Inc., confirming the declarations under Item 8.01 (Other Events). The filing reiterates that MetLife's common stock is traded on the NYSE under ticker MET with a par value of $0.01 per share.
📅 MetLife filed SEC Form 8-K on August 17, 2026 for preferred stock dividends.
💰 Series A received a quarterly dividend of $0.3147 per share.
📉 Series D declared a semi-annual dividend of $29.375 per share.
💵 Series E granted a quarterly dividend of $351.56 per share.
📊 Series F declared a quarterly dividend of $296.88 per share.
📅 On August 17, 2026, MetLife filed an SEC Form 8-K to declare dividends for four preferred stock series.
💰 Series A received a quarterly dividend of $0.31471411 per share on its Floating Rate Non-Cumulative Preferred Stock.
📉 Series D declared a semi-annual dividend of $29.375 per share on its 5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock.
💵 Series E was granted a quarterly dividend of $351.5625 per share on its 5.625% Non-Cumulative Preferred Stock.
📊 Series F declared a quarterly dividend of $296.875 per share on its 4.75% Non-Cumulative Preferred Stock.
🏢 All preferred stock declarations were filed under Item 8.01 (Other Events) of the Form 8-K.
📝 The filing was signed by Timothy J. Ring, Senior Vice President and Secretary of MetLife, Inc.
Bullish Signals
MetLife declared dividends for four preferred stock series on Aug 17, 2026.
Active management confirmed via quarterly and semi-annual dividend declarations.
Bullish Signals
MetLife successfully declared dividends for four distinct preferred stock series (A, D, E, and F) on August 17, 2026, demonstrating the company's ability to meet its capital distribution obligations.
The declaration of specific quarterly and semi-annual dividend rates confirms the active management of MetLife's preferred equity structure and adherence to shareholder agreements.
Bank of Nova Scotia significantly reduced its stake in MetLife, Inc. (NYSE:MET) by 42.1% during the first quarter, selling 155,705 shares to hold a remaining position of 213,846 shares valued at $15.1 million. Conversely, several smaller institutional investors and wealth management firms increased their holdings in the fourth quarter, with Activest Wealth Management boosting its stake by over 200% to own 315 shares.
Wall Street analysts have recently issued mixed but generally positive signals for MetLife. Major institutions including JPMorgan Chase, Wells Fargo, and Jefferies Financial Group raised their price targets to between $101 and $106, maintaining 'overweight' or 'buy' ratings. The consensus average price target stands at $100.50 with a 'Moderate Buy' rating, though Wall Street Zen recently downgraded the stock to a 'hold'.
MetLife reported quarterly earnings on May 6th that beat EPS expectations of $2.27 with a result of $2.42, although revenue of $14.18 billion missed analyst estimates of $19.49 billion. The company maintains a market capitalization of $60.91 billion and has announced a quarterly dividend of $0.5925 per share payable on September 8th to shareholders of record on August 4th.
📉 Bank of Nova Scotia sold 155,705 shares, retaining $15.1M stake.
📈 Activest Wealth Management increased holdings by 205.8% to $25,000.
💰 Analysts raised price targets to average $100.50 with 'Moderate Buy' rating.
📊 MetLife Q1 EPS beat estimates while revenue missed consensus.
💵 Company declared quarterly dividend of $0.5925 per share.
📉 Bank of Nova Scotia decreased its MetLife position by 42.1% in Q1, selling 155,705 shares while retaining a stake worth $15.1 million.
📈 Activest Wealth Management increased its MetLife holdings by 205.8% in Q4 to own 315 shares valued at $25,000.
💰 JPMorgan Chase raised its price target on MetLife from $96.00 to $106.00 with an 'overweight' rating.
📊 Wells Fargo increased its target price from $95.00 to $101.00 and maintained an 'overweight' stance.
🎯 Piper Sandler boosted its price target to $90.00 while keeping a 'neutral' rating on the stock.
📉 MetLife reported Q1 EPS of $2.42, beating estimates, but revenue of $14.18 billion missed the $19.49 billion consensus.
💵 The company declared a quarterly dividend of $0.5925 per share with an annualized yield of 2.5%.
📈 MetLife's stock trades at a P/E ratio of 18.35 with a market cap of $60.91 billion.
🏦 Hedge funds and institutional investors collectively own 94.99% of the company's outstanding shares.
🗣️ Analyst consensus currently rates MetLife as a 'Moderate Buy' with an average price target of $100.50.
Bullish Signals
JPMorgan raised target to $106 with 'overweight' rating.
Wells Fargo increased target to $101, signaling positive outlook.
Jefferies raised target to $103 and upgraded to 'buy'.
MetLife beat EPS estimates, reporting $2.42 per share.
Company maintains 22.60% ROE and 4.66% net margin.
Activest Wealth increased stake by over 200%.
MetLife offers 2.5% dividend yield with 45.93% payout ratio.
Risk Factors
Bank of Nova Scotia cut position by 42.1% in Q1.
MetLife revenue of $14.18B missed $19.49B estimates significantly.
Wall Street Zen downgraded stock from buy to hold.
Stock nears 52-week high of $94.86, limiting upside.
Bullish Signals
JPMorgan Chase raised its price target to $106.00 and assigned an 'overweight' rating, indicating strong institutional confidence.
Wells Fargo increased its price target to $101.00 with an 'overweight' rating, signaling positive outlook from major banks.
Jefferies Financial Group raised its target price to $103.00 and upgraded the rating to 'buy'.
MetLife beat quarterly EPS estimates of $2.27 by reporting $2.42 per share.
The company maintains a healthy return on equity of 22.60% and a net margin of 4.66%.
Activest Wealth Management significantly increased its stake by over 200%, suggesting bullish sentiment among smaller funds.
MetLife offers a consistent dividend yield of 2.5% with a payout ratio of 45.93%.
Risk Factors
Bank of Nova Scotia reduced its position by 42.1% in Q1, indicating a lack of interest from one of the largest institutional holders.
MetLife's quarterly revenue of $14.18 billion missed analyst estimates of $19.49 billion significantly.
Wall Street Zen downgraded MetLife from 'buy' to 'hold', reflecting some caution among analysts.
The stock is trading near its 52-week high of $94.86, which may limit immediate upside potential.
Andra AP fonden established a new position in MetLife, Inc. (NYSE:MET) by purchasing 31,400 shares valued at approximately $2.22 million during the first quarter, according to recent SEC filings. Several other institutional investors also increased their stakes in the fourth quarter, including Activest Wealth Management which lifted its holdings by over 200%, and Sound Income Strategies LLC which boosted its stake by nearly 60%. These new positions indicate growing institutional interest in the financial services provider.
Analyst sentiment remains predominantly positive with major firms raising price targets and maintaining buy ratings. Jefferies Financial Group increased its target price to $103, while TD Cowen raised its objective to $105. Weiss Ratings upgraded MetLife from a 'buy (b-)' to a 'buy (b)', and UBS Group lifted its price objective to $105. The consensus average rating is currently a 'Moderate Buy' with an average target price of $100.50, suggesting analysts see potential upside from current levels.
MetLife recently reported earnings for the quarter ended May 6th, posting EPS of $2.42 which beat analyst estimates of $2.27. However, revenue came in at $14.18 billion, significantly below the consensus estimate of $19.49 billion, though it represented a 2.7% year-over-year increase. The company maintains a market capitalization of $59.61 billion and has declared a quarterly dividend of $0.5925 per share payable on September 8th to shareholders of record on August 4th.
📈 Andra AP fonden bought 31,400 MetLife shares worth $2.22 million in Q1.
📊 Activest Wealth Management holdings surged 205.8% while Sound Income Strategies rose 58.9%.
💰 MetLife beat EPS estimates at $2.42 but missed revenue targets of $19.49 billion.
💵 Quarterly dividend is $0.5925 per share with a 2.6% annualized yield.
🏦 Global insurance provider headquartered in New York City with $59.61 billion market cap.
📈 Andra AP fonden purchased a new position in MetLife consisting of 31,400 shares valued at approximately $2.22 million during the first quarter.
📊 Activest Wealth Management increased its holdings by 205.8% in the fourth quarter, while Sound Income Strategies LLC boosted its stake by 58.9%.
📈 Jefferies Financial Group raised its price target to $103 and TD Cowen increased its objective to $105, both maintaining buy ratings.
💰 MetLife reported quarterly EPS of $2.42, beating analyst estimates of $2.27, though revenue of $14.18 billion missed the consensus forecast of $19.49 billion.
📉 The stock has a 52-week high of $94.86 and a low of $67.33, currently trading with a market cap of $59.61 billion.
💵 MetLife declared a quarterly dividend of $0.5925 per share, representing an annualized yield of 2.6% payable on September 8th.
🏦 The company operates as a global provider of insurance, annuities, and employee benefit programs with headquarters in New York City.
📉 Revenue for the quarter was up 2.7% compared to the same period last year despite missing absolute analyst expectations.
Bullish Signals
Activest Wealth Management increased stake by over 200%.
Weiss Ratings upgraded MetLife to a 'buy (b)' rating.
MetLife beat EPS estimates with reported $2.42 vs $2.27.
Solid dividend yield of 2.6% with 45.93% payout ratio.
Revenue grew 2.7% year-over-year to $14.18 billion.
Risk Factors
Revenue of $14.18B missed consensus estimate of $19.49B.
Bank of America lowered price target from $103.00 to $99.00.
Bullish Signals
Andra AP fonden initiated a significant new position of $2.22 million, signaling strong institutional confidence in the company.
Activest Wealth Management increased its stake by over 200% and Sound Income Strategies LLC boosted holdings by nearly 60% in the fourth quarter.
Jefferies Financial Group raised its price target to $103 and TD Cowen lifted its objective to $105, both reaffirming buy ratings.
Weiss Ratings upgraded MetLife from a 'buy (b-)' to a 'buy (b)', indicating improved credit or fundamental outlook.
MetLife beat quarterly earnings per share estimates with reported EPS of $2.42 versus the consensus of $2.27.
The company maintains a solid dividend yield of 2.6% with a payout ratio of 45.93%, providing income to shareholders.
Revenue grew by 2.7% year-over-year to $14.18 billion, demonstrating organic business growth despite missing absolute targets.
The average analyst price target of $100.50 suggests potential upside from recent trading levels.
Risk Factors
MetLife's quarterly revenue of $14.18 billion significantly missed the analyst consensus estimate of $19.49 billion.
Bank of America lowered its price target on MetLife shares from $103.00 to $99.00, though it maintained a buy rating.
Dimensional Fund Advisors LP reduced its position in MetLife, Inc. (NYSE:MET) by 5.1% during the first quarter, selling 383,075 shares to hold approximately 7.12 million shares valued at $503.64 million, representing about 1.09% of the company's outstanding stock.
Several other institutional investors adjusted their stakes in MetLife during the fourth quarter, with Strs Ohio increasing holdings by 16.6%, Evergreen Capital Management rising its stake by 195.8%, and PFA Pension Forsikringsaktieselskab establishing a new position valued at $81.49 million.
MetLife shares opened at $93.00, trading above its 50-day moving average of $86.11 and 200-day moving average of $79.16, with a market capitalization of $59.84 billion and a P/E ratio of 18.02.
The company announced a quarterly dividend of $0.5925 per share payable on September 8th to stockholders of record as of August 4th, resulting in an annualized dividend yield of 2.5% and a payout ratio of 45.93%.
📉 DFA sold 383,075 shares, reducing stake by 5.1%.
🚀 Evergreen Capital boosted holdings by 195.8% with 22,016 shares.
💰 PFA Pension entered new position valued at $81.49 million.
💵 Quarterly dividend of $0.5925 payable on September 8th.
📉 Dimensional Fund Advisors LP reduced its MetLife stake by 5.1%, selling 383,075 shares in the first quarter.
📈 Strs Ohio increased its MetLife holdings by 16.6% to own 326,091 shares worth $25.74 million.
🚀 Evergreen Capital Management LLC boosted its stake by 195.8%, acquiring an additional 22,016 shares.
💰 PFA Pension Forsikringsaktieselskab acquired a new position in MetLife valued at $81.49 million.
📊 Diversified Trust Co. increased its stake by 276.4% to own 31,246 shares worth $2.47 million.
🏢 Universal Beteiligungs und Servicegesellschaft mbH raised its stake by 2.1% to hold 714,193 shares.
📉 MetLife stock opened at $93.00 with a market cap of $59.84 billion and a P/E ratio of 18.02.
💵 The company declared a quarterly dividend of $0.5925 per share payable on September 8th.
📈 Analyst consensus target price is $98.57 with an average rating of 'Moderate Buy' from Wall Street Zen and others.
🏛️ MetLife maintains a debt-to-equity ratio of 0.53 and a quick ratio of 0.20.
Bullish Signals
Trading above 50-day ($86.11) and 200-day ($79.16) moving averages.
Analyst target price $98.57 with upgrades to $105.00 and $94.00.
Institutional ownership stands high at 94.99%.
Dividend yield of 2.5% with sustainable 45.93% payout ratio.
Risk Factors
Major holder DFA cut position by 5.1%, selling 383k shares.
Current and quick ratios at 0.20 signal severe liquidity risks.
Bullish Signals
MetLife shares are trading above both the 50-day moving average ($86.11) and the 200-day moving average ($79.16), indicating positive short-to-medium-term momentum.
The company has a strong analyst consensus with an average target price of $98.57, supported by upgrades from Keefe, Bruyette & Woods to $105.00 and Barclays to $94.00.
Institutional ownership remains high at 94.99%, demonstrating continued confidence from major investors despite some position reductions.
MetLife offers a solid dividend yield of 2.5% with a sustainable payout ratio of 45.93%, providing income to shareholders.
Risk Factors
Dimensional Fund Advisors LP, a significant institutional holder, reduced its position by 5.1% in the first quarter, selling over 383,000 shares.
The company's current ratio and quick ratio are both at 0.20, indicating potential liquidity constraints relative to short-term obligations.
Boston Common Asset Management LLC reduced its stake in MetLife, Inc. (NYSE:MET) by 11.2% during the first quarter, selling 13,810 shares to hold a remaining position of 109,516 shares valued at $7.745 million according to recent SEC filings.
Conversely, several smaller institutional investors increased their positions in MetLife during the fourth quarter. Activest Wealth Management raised its stake by 205.8% to own 315 shares worth $25,000, while Sound Income Strategies LLC grew its holding by 58.9% to 383 shares valued at $29,000.
MetLife recently reported quarterly earnings on May 6th, posting $2.42 per share which beat the consensus estimate of $2.27. However, revenue came in at $14.18 billion, significantly below the expected $19.49 billion, resulting in a net margin of 4.66% and year-over-year revenue growth of only 2.7%.
The company maintains a market capitalization of $60.48 billion with a dividend yield of 2.5%, set to be paid on September 8th to shareholders of record on August 4th. MetLife trades at a PE ratio of 18.21 and has seen its stock price fluctuate between a one-year low of $67.33 and a high of $94.86.
📉 Boston Common Asset Management reduced MetLife stake by 11.2% to 109,516 shares.
📈 Activest Wealth Management increased position by 205.8% to 315 shares.
📊 Q1 EPS beat estimates at $2.42 despite revenue miss of $14.18 billion.
💰 Quarterly dividend declared at $0.5925 per share with 2.5% yield.
🏢 Global insurance provider headquartered in New York City with $60.48B market cap.
📉 Boston Common Asset Management LLC trimmed its MetLife stake by 11.2% in Q1, reducing holdings to 109,516 shares valued at $7.745 million.
📈 Activest Wealth Management significantly increased its position by 205.8% in Q4, now owning 315 shares worth $25,000.
📊 MetLife reported Q1 EPS of $2.42, beating analyst estimates of $2.27 despite revenue missing expectations at $14.18 billion versus a consensus of $19.49 billion.
💰 The company declared a quarterly dividend of $0.5925 per share, offering a 2.5% yield to shareholders of record on August 4th.
📈 MetLife shares currently trade at a PE ratio of 18.21 with a market capitalization of $60.48 billion.
🏢 The firm operates as a global provider of insurance, annuities, and employee benefit programs headquartered in New York City.
Bullish Signals
MetLife beat EPS estimates by $0.15 at $2.42.
Strong ROE of 22.60% with manageable debt-to-equity of 0.53.
Institutional investors Activest Wealth and Sound Income increased stakes.
Risk Factors
Q1 revenue missed estimates by $5.31 billion.
Year-over-year revenue growth was only 2.7%.
Bullish Signals
MetLife beat quarterly earnings per share estimates by $0.15, reporting $2.42 EPS against a consensus of $2.27.
The company maintains a strong return on equity of 22.60% and a manageable debt-to-equity ratio of 0.53.
Activest Wealth Management and Sound Income Strategies LLC increased their stakes, indicating continued institutional interest in the stock.
Risk Factors
MetLife's Q1 revenue of $14.18 billion fell significantly short of the consensus estimate of $19.49 billion.
The company's year-over-year revenue growth was modest at only 2.7% compared to the same quarter last year.
AIA Group Ltd significantly increased its stake in MetLife, Inc. (NYSE: MET) by 150% during the first quarter, purchasing an additional 114,997 shares to hold a total of 191,638 shares valued at $13.55 million. Several other institutional investors also adjusted their positions, with Empowered Funds LLC increasing its stake by 187.6% and new stakes taken by Sivia Capital Partners LLC and Jump Financial LLC in the second quarter.
MetLife reported quarterly earnings on May 6th, posting $2.42 per share which beat analyst consensus estimates of $2.27. However, revenue came in at $14.18 billion, falling short of the estimated $19.49 billion, resulting in a year-over-year revenue increase of only 2.7%. The company achieved a net margin of 4.66% and a return on equity of 22.60%, with analysts forecasting full-year earnings of $9.94 per share.
The stock recently opened at $93.99, trading near its 12-month high of $94.86 with a market capitalization of $60.48 billion and a P/E ratio of 18.21. MetLife maintains a dividend yield of 2.5% with an upcoming payment of $0.5925 per share to stockholders of record on August 4th, reflecting a payout ratio of 45.93%. The company operates as a global provider of insurance, annuities, and employee benefit programs headquartered in New York City.
📈 AIA Group boosted MetLife holdings by 150% in Q1.
📉 Revenue missed estimates at $14.18 billion despite beating EPS.
💰 EPS of $2.42 surpassed consensus estimate of $2.27.
💵 Stock trades at P/E of 18.21 with $60.48B market cap.
📅 Quarterly dividend of $0.5925 payable Sept 8th to record holders.
📈 AIA Group Ltd boosted its MetLife holdings by 150% in Q1, adding 114,997 shares to a total position of 191,638 shares.
📉 MetLife reported revenue of $14.18 billion for the quarter, which missed analyst estimates of $19.49 billion despite beating EPS expectations.
💰 The company posted earnings per share of $2.42, surpassing the consensus estimate of $2.27 by $0.15.
📊 MetLife achieved a net margin of 4.66% and a return on equity of 22.60% during the reported quarter.
💵 The stock trades at a P/E ratio of 18.21 with a market capitalization of $60.48 billion.
📅 MetLife announced a quarterly dividend of $0.5925 per share payable on September 8th to record holders as of August 4th.
🏦 The company maintains a debt-to-equity ratio of 0.53 and a current ratio of 0.20.
📈 Analysts forecast full-year earnings of $9.94 per share for MetLife, Inc.
Bullish Signals
Institutional stake surged 150% in Q1.
Beat EPS estimates at $2.42 vs $2.27.
Healthy ROE of 22.60% and net margin of 4.66%.
Attractive 2.5% dividend yield with 45.93% payout.
Risk Factors
Revenue missed estimates: $14.18B vs $19.49B expected.
Modest YoY growth of only 2.7%.
Bullish Signals
AIA Group Ltd increased its stake in MetLife by 150% in the first quarter, signaling strong institutional confidence in the financial services provider.
MetLife beat quarterly earnings estimates with $2.42 EPS compared to the consensus of $2.27.
The company maintains a healthy return on equity of 22.60% and a net margin of 4.66%.
MetLife offers an attractive dividend yield of 2.5% with a sustainable payout ratio of 45.93%.
Risk Factors
MetLife's quarterly revenue of $14.18 billion significantly missed analyst estimates of $19.49 billion, indicating potential headwinds in core business segments.
The company's year-over-year revenue growth was modest at only 2.7%, suggesting limited expansion momentum.
Bank of New York Mellon Corp reduced its stake in MetLife, Inc. (NYSE:MET) by 25.8% during the first quarter, selling over 1.24 million shares to hold a remaining position valued at approximately $253 million. Conversely, several other major institutional investors increased their holdings significantly in the fourth and third quarters, including Vanguard Group, which added roughly 7.8 million shares worth nearly $5.7 billion, and Pzena Investment Management, which boosted its position by 22.9%.
MetLife's stock recently opened at $93.99 with a market capitalization of $60.48 billion. The company maintains a dividend yield of 2.5%, set to pay $0.5925 per share on September 8th for shareholders of record on August 4th. Analyst sentiment remains generally positive, with an average target price of $98.57 and a consensus rating of 'Moderate Buy' from Wall Street firms like UBS and Jefferies.
MetLife operates as a global provider of insurance, annuities, and employee benefit programs headquartered in New York City. Its core business segments include life insurance, group benefits, retirement products such as annuities, and supplemental health coverage including dental and disability plans distributed through employer-sponsored programs.
📉 BNY Mellon sold 1.24M shares, retaining $253M stake.
📈 Vanguard added 7.8M shares worth $5.7B in Q4.
📈 Pzena raised position by 22.9% to own $938M.
💰 MetLife pays $0.5925 dividend with 2.5% yield.
📊 Stock trades at 18.21 P/E ratio and $60.48B cap.
📉 Bank of New York Mellon Corp reduced its MetLife holdings by 25.8% in Q1, selling 1,241,561 shares while retaining a $253 million position.
📈 Vanguard Group increased its stake by 12.1% in Q4, adding 7,805,814 shares valued at approximately $5.7 billion.
📈 Pzena Investment Management LLC raised its position by 22.9% in Q4 to own 11,883,338 shares worth roughly $938 million.
📈 AQR Capital Management and Man Group plc also significantly increased their MetLife positions during the third and second quarters respectively.
💰 MetLife announced a quarterly dividend of $0.5925 per share with an ex-dividend date of August 4th, offering a 2.5% yield.
📊 The stock trades at a P/E ratio of 18.21 and has a market cap of $60.48 billion as of the latest trading session.
🏦 UBS Group raised its price target to $105.00 with a 'buy' rating, while Jefferies Financial Group set a $103.00 objective.
📉 Wall Street Zen downgraded MetLife from 'buy' to 'hold', though the average analyst consensus remains a 'Moderate Buy'.
Bullish Signals
Major investors like Vanguard increased stakes in MetLife.
Solid 2.5% dividend yield with 45.93% payout ratio.
UBS and Jefferies issued buy ratings with raised targets.
Strong global market position in life insurance and annuities.
Risk Factors
BNY Mellon cut holdings by over 25% in Q1.
Wall Street Zen downgraded stock from buy to hold.
Bullish Signals
Major institutional investors like Vanguard, Pzena, and AQR have increased their stakes in MetLife during recent quarters, indicating continued confidence in the company's long-term prospects.
MetLife maintains a solid dividend yield of 2.5% with a payout ratio of 45.93%, providing consistent income to shareholders.
Multiple brokerages including UBS and Jefferies have issued 'buy' ratings and raised price targets above the current trading price.
The company holds a strong market position as a global provider of life insurance, annuities, and employee benefit programs.
Risk Factors
Bank of New York Mellon Corp significantly reduced its holdings by over 25% in Q1, signaling a lack of confidence from at least one major institutional investor.
Wall Street Zen downgraded the stock from 'buy' to 'hold', reflecting some divergence in analyst sentiment regarding the company's valuation or outlook.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
